Table 1 Overall baseline characteristics according to SVR status
Parameters | Overall (n = 985) | SVR (n = 966) | No SVR (n = 19) |
|---|---|---|---|
Sex, n (%) | |||
M | 543 (55.1) | 529 (54.8) | 14 (73.7) |
F | 442 (44.9) | 437 (45.2) | 5 (26.3) |
Age, years, median [IQR] | 67 [59–73] | 67 [59–73] | 66 [60–71] |
BMI, kg/m2, median [IQR] | 26 [24–28.4] | 26 [24–28.3] | 27 [23.3–30.6] |
Diabetes, n (%) | 131 (13.3) | 129 (13.4) | 2 (10.5) |
Metabolic syndrome, n (%) | 69 (8) | 69 (8.1) | – |
Liver disease stage, n (%) | |||
Advanced fibrosis | 254 (25.8) | 252 (26.1) | 2 (10.5) |
Cirrhosis | 731 (74.2) | 714 (73.9) | 17 (89.5) |
HCV genotype, n (%) | |||
1 | 765 (77.7) | 754 (78.1) | 12 (63.2) |
2 | 160 (16.2) | 155 (16.1) | 4 (21.1) |
3 | 50 (5.1) | 47 (4.9) | 3 (15.8) |
4 | 10 (1.0) | 10 (1.0) | 0 |
Liver stiffness, kPa, median [IQR] | 17.3 [11.9–35.3] | 16 [11.8–23] | 23.4 [14.6–41.7] |
Treatment duration, n (%) (weeks) | |||
12 | 612 (62.1) | 603 (62.4) | 9 (47.4) |
24 | 373 (37.9) | 363 (37.6) | 10 (52.6) |
SVR12, n (%) | 966 (98.1) | ||
DAAs regimen, n (%) | |||
SOF/RBV (dual) | 417 (42.3) | 408 (42.2) | 10 (52.6) |
SOF/LDV ± RBV | 183 (18.6) | 186 (19.3) | 3 (15.8) |
SOF/DCV ± RBV | 39 (4.0) | 33 (3.4) | 0 (0.0) |
SOF/SIM ± RBV | 99 (10.1) | 97 (10) | 2 (10.5) |
2D/3D ± RBV | 247 (25.0) | 242 (25.1) | 4 (21.1) |
Treatment classes, n (%) | |||
SOF based | 738 (74.9) | 723 (74.8) | 15 (78.9) |
RBV included | 705 (71.6) | 693 (71.7) | 12 (63.2) |
SOF/RBV (all) | 573 (58.2) | 561 (58.1) | 12 (63.2) |
HCC occurrence, n (%) | 35 (3.6) | 35 (3.6) | 0 (0) |